SCHEMBL17228686

SCHEMBL17228686

Cc1ncnc(C)c1-c1ccc(Oc2ncnn3cccc23)c(F)c1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 4/20 0.44
ALDH1A1 P00352 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MAPK1 P28482 1/20 0.41
MET P08581 2/20 0.39
EGFR P00533 2/20 0.37
KDR P35968 2/20 0.37
TRPA1 O75762 5/20 0.36
DRD1 P21728 1/20 0.34
MRGPRX1 Q96LB2 1/20 0.34
NPC1 O15118 1/20 0.34
NFKB1 P19838 1/20 0.34
RAB9A P51151 1/20 0.34
NFKB2 Q00653 1/20 0.34
RELA Q04206 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17228683 0.85 DRD1 (0.50) MAP4K4ALDH1A1KDM4EMAPK1MET
SCHEMBL17228687 0.81 DRD1 (0.41) ALDH1A1KDM4ETRPA1DRD1NPC1
SCHEMBL17228684 0.81 MAP4K4 (0.44) MAP4K4METEGFRKDRDRD1
SCHEMBL4818237 0.81 MAP4K4 (0.48) MAP4K4METEGFRKDRTRPA1
SCHEMBL17228773 0.80 DRD1 (0.50) MAP4K4DRD1
SCHEMBL4817688 0.76 MAP4K4 (0.44) MAP4K4ALDH1A1MAPK1METEGFR
SCHEMBL17228660 0.74 DRD1 (0.54) MAP4K4DRD1
SCHEMBL17228772 0.74 DRD1 (0.50) MAP4K4DRD1
SCHEMBL17228688 0.73 DRD1 (0.50) MAP4K4EGFRKDRDRD1
SCHEMBL17228690 0.71 DRD1 (0.53) MAP4K4DRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9856263-B2 Heteroaromatic compounds and their use as dopamine D1 ligands PFIZER INC. (US) 2018-01-02 US disclosed
US-9856263-B2 Heteroaromatic compounds and their use as dopamine D1 ligands PFIZER INC. (US) 2018-01-02 US disclosed
US-20170037049-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER INC. (US) 2017-02-09 US disclosed
US-20170037049-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER INC. (US) 2017-02-09 US disclosed
US-20170037049-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER INC. (US) 2017-02-09 US disclosed
WO-2015166370-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER INC. (US) 2015-11-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170037049-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS DRD2, DRD1, DRD4 MAP4K4 1966/4885ALDH1A1 99/4885KDM4E 4663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.